Biological Innovation for Open Society
BiOS is an international initiative to foster innovation and freedom to operate in the biological sciences. BiOS was officially launched on 10 February 2005 by Cambia, an independent, international non-profit organization dedicated to democratizing innovation. Its intention is to initiate new norms and practices for creating tools for biological innovation, using binding covenants to protect and preserve their usefulness, while allowing diverse business models for the application of these tools.
As described by Richard Anthony Jefferson, CEO of Cambia, the Deputy CEO of Cambia, Dr Marie Connett worked extensively with small companies, university offices of technology transfer, attorneys, and multinational corporations to create a platform to share productive and sustainable technology. The parties developed the BiOS Material Transfer Agreement and the BiOS license as legal instruments to facilitate these goals.
BiOS License
By making the BiOS license cost-free, Cambia has sought to create 'freedom to innovate' in the scientific community. In lieu of royalties and other restrictions often imposed by legal agreements, the BiOS licenses impose on the licensee conditions to encourage cooperation and development of the technology. To be granted full, unfettered commercial rights to listed technologies, licensees are required to comply with three conditions:- To share with all BiOS licensees any improvements in the core technologies as defined, for which they seek any Intellectual Property protection.
- To agree to not assert over other BiOS licensees their own or third-party rights that might dominate the defined technologies.
- To agree to share with the public any and all information about the biosafety of the defined technologies.
The adoption of the BiOS licenses has now extended to over 300 licensees worldwide.